A detailed history of Amalgamated Bank transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,887 shares of VNDA stock, worth $9,151. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,887
Previous 1,887 -0.0%
Holding current value
$9,151
Previous $11,000 18.18%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$3.47 - $4.61 $10,489 - $13,936
-3,023 Reduced 61.57%
1,887 $8,000
Q4 2023

Feb 06, 2024

SELL
$3.38 - $4.58 $1,896 - $2,569
-561 Reduced 10.25%
4,910 $21,000
Q3 2023

Nov 08, 2023

SELL
$4.28 - $6.57 $74,690 - $114,653
-17,451 Reduced 76.13%
5,471 $24,000
Q2 2023

Aug 11, 2023

SELL
$5.9 - $6.95 $3,764 - $4,434
-638 Reduced 2.71%
22,922 $151,000
Q1 2023

May 02, 2023

SELL
$6.18 - $7.99 $11,012 - $14,238
-1,782 Reduced 7.03%
23,560 $160,000
Q3 2022

Nov 09, 2022

BUY
$9.44 - $11.76 $1,189 - $1,481
126 Added 0.5%
25,342 $250,000
Q2 2022

Aug 15, 2022

BUY
$9.31 - $11.84 $4,841 - $6,156
520 Added 2.11%
25,216 $275,000
Q1 2022

Jun 30, 2022

SELL
$10.84 - $16.55 $15,989 - $24,411
-1,475 Reduced 5.64%
24,696 $279,000
Q4 2021

Feb 15, 2022

SELL
$15.69 - $21.14 $7,986 - $10,760
-509 Reduced 1.91%
26,171 $411,000
Q3 2021

Oct 29, 2021

SELL
$15.35 - $21.27 $6,477 - $8,975
-422 Reduced 1.56%
26,680 $457,000
Q2 2021

Aug 16, 2021

BUY
$15.71 - $21.51 $425,772 - $582,964
27,102 New
27,102 $583,000
Q1 2020

May 13, 2020

SELL
$7.5 - $16.8 $75,630 - $169,411
-10,084 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$12.38 - $17.47 $124,839 - $176,167
10,084 New
10,084 $165,000
Q1 2019

May 15, 2019

SELL
$17.59 - $31.05 $144,361 - $254,827
-8,207 Closed
0 $0
Q4 2018

Feb 15, 2019

BUY
$18.97 - $31.47 $155,686 - $258,274
8,207 New
8,207 $214,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $274M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.